157 related articles for article (PubMed ID: 34226433)
1. Duration of inactive disease while off disease-modifying anti-rheumatic drugs seems to influence flare rates in juvenile idiopathic arthritis: an observational retrospective study.
Aires PP; Terreri MTRA; Silva VBM; Vieira MM; Len CA
Acta Reumatol Port; 2021; 46(2):120-125. PubMed ID: 34226433
[TBL] [Abstract][Full Text] [Related]
2. Discontinuation of biologic DMARDs in non-systemic JIA patients: a scoping review of relapse rates and associated factors.
Gieling J; van den Bemt B; Hoppenreijs E; Schatorjé E
Pediatr Rheumatol Online J; 2022 Dec; 20(1):109. PubMed ID: 36471348
[TBL] [Abstract][Full Text] [Related]
3. Impact of medication withdrawal method on flare-free survival in patients with juvenile idiopathic arthritis on combination therapy.
Chang CY; Meyer RM; Reiff AO
Arthritis Care Res (Hoboken); 2015 May; 67(5):658-66. PubMed ID: 25220674
[TBL] [Abstract][Full Text] [Related]
4. Treatment Withdrawal Following Remission in Juvenile Idiopathic Arthritis: A Systematic Review of the Literature.
Halyabar O; Mehta J; Ringold S; Rumsey DG; Horton DB
Paediatr Drugs; 2019 Dec; 21(6):469-492. PubMed ID: 31673960
[TBL] [Abstract][Full Text] [Related]
5. Predictors of Flare Following Etanercept Withdrawal in Patients with Rheumatoid Factor-negative Juvenile Idiopathic Arthritis Who Reached Remission while Taking Medication.
Aquilani A; Marafon DP; Marasco E; Nicolai R; Messia V; Perfetti F; Magni-Manzoni S; De Benedetti F
J Rheumatol; 2018 Jul; 45(7):956-961. PubMed ID: 29717035
[TBL] [Abstract][Full Text] [Related]
6. When to stop medication in juvenile idiopathic arthritis.
Abel D; Weiss PF
Curr Opin Rheumatol; 2023 Sep; 35(5):265-272. PubMed ID: 37139831
[TBL] [Abstract][Full Text] [Related]
7. Effects of tapering conventional synthetic disease-modifying antirheumatic drugs to drug-free remission versus stable treatment in rheumatoid arthritis (ARCTIC REWIND): 3-year results from an open-label, randomised controlled, non-inferiority trial.
Kjørholt KE; Sundlisæter NP; Aga AB; Sexton J; Olsen IC; Fremstad H; Spada C; Madland TM; Høili CA; Bakland G; Lexberg Å; Hansen IJW; Hansen IM; Haukeland H; Ljoså MA; Moholt E; Uhlig T; Kvien TK; Solomon DH; van der Heijde D; Haavardsholm EA; Lillegraven S
Lancet Rheumatol; 2024 May; 6(5):e268-e278. PubMed ID: 38583450
[TBL] [Abstract][Full Text] [Related]
8. Clinical remission and subsequent relapse in patients with juvenile idiopathic arthritis: predictive factors according to therapeutic approach.
Castillo-Vilella M; Giménez N; Tandaipan JL; Quintana S; Modesto C
Pediatr Rheumatol Online J; 2021 Aug; 19(1):130. PubMed ID: 34419078
[TBL] [Abstract][Full Text] [Related]
9. Re-treatment with etanercept is as effective as the initial firstline treatment in patients with juvenile idiopathic arthritis.
Klotsche J; Klein A; Niewerth M; Hoff P; Windschall D; Foeldvari I; Haas JP; Horneff G; Minden K
Arthritis Res Ther; 2021 Apr; 23(1):118. PubMed ID: 33863349
[TBL] [Abstract][Full Text] [Related]
10. Disease Recapture Rates After Medication Discontinuation and Flare in Juvenile Idiopathic Arthritis: An Observational Study Within the Childhood Arthritis and Rheumatology Research Alliance Registry.
Ringold S; Dennos AC; Kimura Y; Beukelman T; Shrader P; Phillips TA; Kohlheim M; Schanberg LE; Yeung RSM; Horton DB;
Arthritis Care Res (Hoboken); 2023 Apr; 75(4):715-723. PubMed ID: 35921198
[TBL] [Abstract][Full Text] [Related]
11. Serum S100A8/A9 and S100A12 Levels in Children With Polyarticular Forms of Juvenile Idiopathic Arthritis: Relationship to Maintenance of Clinically Inactive Disease During Anti-Tumor Necrosis Factor Therapy and Occurrence of Disease Flare After Discontinuation of Therapy.
Hinze CH; Foell D; Johnson AL; Spalding SJ; Gottlieb BS; Morris PW; Kimura Y; Onel K; Li SC; Grom AA; Taylor J; Brunner HI; Huggins JL; Nocton JJ; Haines KA; Edelheit BS; Shishov M; Jung LK; Williams CB; Tesher MS; Costanzo DM; Zemel LS; Dare JA; Passo MH; Ede KC; Olson JC; Cassidy EA; Griffin TA; Wagner-Weiner L; Weiss JE; Vogler LB; Rouster-Stevens KA; Beukelman T; Cron RQ; Kietz D; Schikler K; Mehta J; Ting TV; Verbsky JW; Eberhard AB; Huang B; Giannini EH; Lovell DJ
Arthritis Rheumatol; 2019 Mar; 71(3):451-459. PubMed ID: 30225949
[TBL] [Abstract][Full Text] [Related]
12. Anti-tumor necrosis factor (aTNF) weaning strategy in juvenile idiopathic arthritis (JIA): does duration matter?
Teh KL; Das L; Book YX; Hoh SF; Gao X; Arkachaisri T
Clin Rheumatol; 2024 May; 43(5):1723-1733. PubMed ID: 38443603
[TBL] [Abstract][Full Text] [Related]
13. Flares After Withdrawal of Biologic Therapies in Juvenile Idiopathic Arthritis: Clinical and Laboratory Correlates of Remission Duration.
Simonini G; Ferrara G; Pontikaki I; Scoccimarro E; Giani T; Taddio A; Meroni PL; Cimaz R
Arthritis Care Res (Hoboken); 2018 Jul; 70(7):1046-1051. PubMed ID: 28973842
[TBL] [Abstract][Full Text] [Related]
14. Attitudes and Approaches for Withdrawing Drugs for Children with Clinically Inactive Nonsystemic JIA: A Survey of the Childhood Arthritis and Rheumatology Research Alliance.
Horton DB; Onel KB; Beukelman T; Ringold S
J Rheumatol; 2017 Mar; 44(3):352-360. PubMed ID: 28148696
[TBL] [Abstract][Full Text] [Related]
15. Factors determining resistance to conventional disease-modifying anti-rheumatic drug treatment in oligoarticular juvenile idiopathic arthritis.
Sener S; Aliyev E; Batu ED; Balik Z; Bayindir Y; Cam V; Basaran O; Bilginer Y; Ozen S
Clin Rheumatol; 2024 Jun; 43(6):2021-2026. PubMed ID: 38683443
[TBL] [Abstract][Full Text] [Related]
16. Time spent in inactive disease before MTX withdrawal is relevant with regard to the flare risk in patients with JIA.
Klotsche J; Minden K; Niewerth M; Horneff G
Ann Rheum Dis; 2018 Jul; 77(7):996-1002. PubMed ID: 29453217
[TBL] [Abstract][Full Text] [Related]
17. Prevention of disease flares by risk-adapted stratification of therapy withdrawal in juvenile idiopathic arthritis: results from the PREVENT-JIA trial.
Gerss J; Tedy M; Klein A; Horneff G; Miranda-Garcia M; Kessel C; Holzinger D; Stanevica V; Swart JF; Cabral DA; Brunner HI; Foell D
Ann Rheum Dis; 2022 Jul; 81(7):990-997. PubMed ID: 35260388
[TBL] [Abstract][Full Text] [Related]
18. Risk, Timing, and Predictors of Disease Flare After Discontinuation of Anti-Tumor Necrosis Factor Therapy in Children With Polyarticular Forms of Juvenile Idiopathic Arthritis With Clinically Inactive Disease.
Lovell DJ; Johnson AL; Huang B; Gottlieb BS; Morris PW; Kimura Y; Onel K; Li SC; Grom AA; Taylor J; Brunner HI; Huggins JL; Nocton JJ; Haines KA; Edelheit BS; Shishov M; Jung LK; Williams CB; Tesher MS; Costanzo DM; Zemel LS; Dare JA; Passo MH; Ede KC; Olson JC; Cassidy EA; Griffin TA; Wagner-Weiner L; Weiss JE; Vogler LB; Rouster-Stevens KA; Beukelman T; Cron RQ; Kietz D; Schikler K; Schmidt KM; Mehta J; Wahezi DM; Ting TV; Verbsky JW; Eberhard BA; Spalding S; Chen C; Giannini EH
Arthritis Rheumatol; 2018 Sep; 70(9):1508-1518. PubMed ID: 29604189
[TBL] [Abstract][Full Text] [Related]
19. Non-systemic juvenile idiopathic arthritis outcome after reaching clinical remission with anti-TNF-α therapy: a clinical practice observational study of patients who discontinued treatment.
Iglesias E; Torrente-Segarra V; Bou R; Ricart S; González MI; Sánchez J; Calzada J; Antón J
Rheumatol Int; 2014 Aug; 34(8):1053-7. PubMed ID: 24162563
[TBL] [Abstract][Full Text] [Related]
20. Withdrawal of biologic therapy in juvenile idiopathic arthritis due to remission: predictors of flare and outcomes.
Tanatar A; Akgün Ö; Çağlayan Ş; Bağlan E; Otar Yener G; Öztürk K; Çakan M; Sönmez HE; Sözeri B; Aktay Ayaz N
Expert Opin Biol Ther; 2023 Mar; 23(3):305-313. PubMed ID: 36825474
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]